Skip to main content
EJNMMI Research

Table 1 Bland–Altman results for the comparison of tracer uptake quantification (%IA/g) assessed by PET imaging and by ex vivo biodistribution for [18F]FDG and [89Zr]Zr-DFO-NCS-trastuzumab

From: Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice

  

PET/CT

PET/MR

18F

89Zr

18F

89Zr

Tumor

Bias ± sd

0.88 ± 0.11

0.76 ± 0.03

0.91 ± 0.11

0.78 ± 0.06

Brain

Bias ± sd

1.07 ± 0.03

2.89 ± 0.46a

1.03 ± 0.10

3.54 ± 0.82a

Kidney

Bias ± sd

0.85 ± 0.11

0.86 ± 0.10

0.89 ± 0.11

0.92 ± 0.10

Liver

Bias ± sd

1.22 ± 0.09

1.06 ± 0.05

1.22 ± 0.15

1.15 ± 0.07

  1. aLarge bias due to denominator of the ratios close to 0%IA/g
Back to article page